Baird lowered the firm’s price target on ResMed (RMD) to $225 from $254 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results and where 2027 oil-related headwinds lowers the outlook.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed price target lowered to $235 from $265 at Stifel
- Analyst Brandon Vazquez Reiterates Buy on ResMed Amid Solid Execution, Margin Expansion, and Attractive Valuation Despite Near-Term Headwinds
- Closing Bell Movers: Apple higher after stronger than expected guidance
- ResMed CFO Brett Sandercock to retire, Aaron Bloomer to succeed
- ResMed Delivers Strong Q3 Results and Margin Expansion